Shop Vielight tech
MCI Clinical Results: Vielight itPBM Improves Memory, Brain Energy, and Inflammation
- Free Webinar: Can itPBM Help Mild Cognitive Impairment (MCI)?
- July 31, 2026, at 2pm EST
- Register here: Link
- Presented by the scientists behind the study, Dr Neda Rashidi-Ranjbar, MD, PhD and Dr Corinne Fischer, MD, PhD – University of Toronto.
For educational purposes only. The Vielight Neuro is a general wellness device and is not intended to diagnose, treat, cure, or prevent Alzheimer’s disease, mild cognitive impairment, or any other condition. This article summarizes an independent, peer-reviewed pilot study with the Vielight Neuro (n = 20) by the University of Toronto and St Michael’s Hospital. Nothing here is medical advice; anyone concerned about memory or cognition should consult a qualified healthcare professional.
Live in Toronto with MCI? Join the followup n=60 clinical trial here: Link
This clinical trial was conducted by:
- Dr Neda Rashidi-Ranjbar, MD, PhD – University of Toronto
- Dr Corinne Fischer, MD, PhD – University of Toronto
Key Findings at a Glance
- Better memory. Significant gains in episodic recognition memory (CVLT-II), one of the first abilities to fade in early Alzheimer’s — large effect size (d = 1.09).
- Improved global cognition. MMSE scores rose while the sham group declined, a difference within the range considered clinically meaningful (d = 1.05).
- More efficient energy production. A lower serum lactate-to-pyruvate ratio — a signature of more efficient, mitochondria-driven energy production (d = −1.37).
- Lower inflammation. A significant drop in IL-6, an inflammatory marker tied to cognitive decline.
- Stronger brain-network connectivity. Increased Default Mode Network connectivity (d = 1.25) — a network disrupted early in Alzheimer’s.
One Study, Three Kinds of Evidence
Most photobiomodulation studies in cognitive decline measure one thing: memory, or a brain scan, or a biomarker. This trial measured all three at once.
Researchers at St. Michael’s Hospital and the University of Toronto, publishing in the Journal of Alzheimer’s Disease (June 2026), ran a randomized, sham-controlled pilot in adults with MCI that tracked cognition, blood-based metabolism, and brain imaging in the same participants. To the authors’ knowledge, it is the first sham-controlled randomized trial of transcranial photobiomodulation in MCI to use this kind of multimodal design.
That design is what gives the results their weight. A single positive memory test can be noise. But when cognition, mitochondrial markers, inflammation, and brain-network connectivity all shift in the same direction in the same people, the findings begin to corroborate one another.
Read the full published study in the Journal of Alzheimer’s Disease here.
Why Mild Cognitive Impairment Is the Window That Matters
MCI is the stage where memory and thinking have measurably slipped, but day-to-day independence is still intact. It often precedes Alzheimer’s disease and related dementias. About 15% of people with MCI progress to dementia within two years, and roughly one-third within five.
The authors frame the problem plainly: by the time dementia symptoms appear, extensive neuronal loss has already happened, which limits how much any treatment can do. That makes the MCI stage a critical, time-sensitive window — and it is why non-invasive, scalable approaches for this group are being actively investigated.
Most therapies in development target amyloid or tau plaques. This trial took a different angle: the mitochondria — the cell’s energy producers — which show dysfunction early in the disease process.
How the Study Was Designed
Twenty adults aged 50–85 with MCI were randomized 1:1 — 10 to active treatment, 10 to a sham (inactive) device. The groups were well matched at baseline for age, sex, education, and cognitive scores, with identical baseline MoCA scores between them.
Participants used a portable Vielight itPBM device with five 810 nm LEDs, full-transcranial scattering: four targeting the medial prefrontal cortex, posterior cingulate cortex, and temporoparietal regions, plus one intranasal emitter targeting the olfactory bulb.
The Results, by Measure
Before and after the six weeks, each participant was assessed the same way: cognitive testing (including the MMSE and the California Verbal Learning Test-II), blood draws, and a full MRI session covering resting-state fMRI, proton MR spectroscopy, and arterial spin labeling. Compared with sham, the active itPBM group showed measurable changes across all three domains the study set out to examine — cognition, blood biomarkers, and brain imaging. Effect sizes (Cohen’s d) are reported as the study gives them; in a pilot this size, large effects signal a strong preliminary result worth confirming, not a settled conclusion.
| Domain | Measure | Result vs. sham | Effect size |
|---|---|---|---|
| Global cognition | MMSE | Improved (+1.5 points vs. sham) | d = 1.05 (p = 0.03) |
| Episodic memory | CVLT-II long-delay recognition | Improved (+3.38 vs. sham) | d = 1.09 (p = 0.02) |
| Mitochondrial metabolism | Serum lactate-to-pyruvate ratio | Decreased (favorable) | d = −1.37 (p = 0.007) |
| Inflammation | Plasma IL-6 | Decreased | r = −0.52 (p = 0.02) |
| Brain connectivity | Default Mode Network functional connectivity | Increased | d = 1.25 (p = 0.014) |
The three sections below walk through each measurement type in turn.
Significant improvements in episodic memory (CVLT-II) and global cognition (MMSE).
1. Cognition: Memory and Global Function
On the MMSE, a standard measure of global cognition, the active group improved by about 1.5 points relative to sham (d = 1.05) — a gain that falls within the 1- to 3-point range considered clinically meaningful in MCI.
The clearest memory signal came from the CVLT-II long-delay recognition task (d = 1.09): more correct recognitions and fewer false positives in the active group, while the sham group declined. Recognition memory is one of the earliest functions to fade in the path toward dementia, which is what makes the result notable.
Two other measures showed large effects favoring active treatment but didn’t reach significance — cued recall (d = 0.98) and executive function on the Trail Making Test-B (d = −0.89).
Serum pyruvate, lactate, and their ratio, active vs. sham — pyruvate rose faster than lactate, lowering the L/P ratio (d = −1.37).
2. Blood Biomarkers: Brain Energy and Inflammation
In the active group, serum pyruvate (pyruvic acid) rose significantly (d = 1.38), and because it outpaced lactate, the lactate-to-pyruvate ratio fell (d = −1.37) — both highly significant (p = 0.007). A lower L/P ratio reflects a shift toward oxidative phosphorylation, the efficient, mitochondria-driven pathway cells use to generate energy. MCI typically shows the inverse — elevated lactate, indicating reliance on less efficient anaerobic metabolism — so the active group’s falling ratio marks a counter to the pattern characteristic of MCI. Because both metabolites cross the blood-brain barrier, serum levels provide a direct window onto that change.
Several supporting metabolites moved in the same direction, each consistent with more efficient aerobic energy production:
- L-carnitine increased — linked to mitochondrial fatty-acid import and β-oxidation
- L-alanine increased — consistent with greater pyruvate processing
- Urea, sarcosine, and glycerol decreased — pointing to reduced amino-acid catabolism and lipolysis
Together these shifts point in one direction: more efficient, mitochondria-driven energy production — measured directly in blood, not inferred from a test score.
Beyond Energy: An Anti-Inflammatory Effect
Chronic inflammation is increasingly recognized as a driver of cognitive decline, not just a byproduct of it. Inflammatory signaling in the brain is associated with faster progression from mild impairment toward dementia, which makes any intervention that lowers it of real interest.
Here, the active group showed a significant decline in plasma IL-6 (r = −0.52, p = 0.02) while the sham group rose. IL-6 is one of the most studied inflammatory cytokines linked to cognitive decline, and its reduction fits the same mitochondrial picture: more efficient energy production is associated with lower oxidative stress and inflammatory signaling.
That the cognitive, metabolic, and inflammatory results all moved together is what makes this trial distinctive. IL-6 was an exploratory endpoint rather than a pre-specified one, so it reads best as a strong signal to confirm in larger trials.
Default Mode Network connectivity, active vs. sham (d = 1.25).
3. Neuroimaging: Brain Networks and Structure
A full MRI session — resting-state fMRI, spectroscopy, and structural scans — bracketed the six weeks of treatment.
The clearest signal was network connectivity. Default Mode Network connectivity increased in the active group (d = 1.25), the network most tied to memory and self-referential thinking, and one of the earliest to break down in Alzheimer’s. Caudate-DMN connectivity rose as well, consistent with stronger integration of memory and cognitive-control circuits.
Structural scans added a parallel finding: increased gray-matter volume in the left nucleus accumbens (d = 1.22) and right thalamus (d = 1.06), and greater cortical thickness in three right-hemisphere regions — including the entorhinal cortex, one of the first areas affected in Alzheimer’s.
Why 810nm, and Why the Nose?
The biology behind itPBM is multifaceted, but two factors stand out in explaining these results:
- The wavelength. Cytochrome c oxidase, the mitochondrial enzyme that drives ATP production, has its near-infrared absorption peak around 810 nm, the wavelength this trial used. Above ~900 nm, that absorption drops sharply and water takes over, so longer wavelengths like 1064–1070 nm are absorbed by tissue water before reaching mitochondria. Independent dosimetry, including Harvard Medical School simulations and cadaver measurements, confirms 810 nm deposits more energy in cortical tissue.
- The delivery route. Only about 1–3% of scalp-applied 810 nm light reaches cortical tissue through skin and skull; Vielight’s intranasal route bypasses that barrier, delivering light to the olfactory bulb, one of the earliest sites of Alzheimer’s-related change, with direct connections to the limbic and prefrontal regions of the Default Mode Network. This route may reach circuits scalp-based light cannot, and the network-level effects seen in the trial may partly reflect it. The paper is one of the few to discuss the rationale for combining transcranial and intranasal delivery — the intranasal-transcranial (itPBM) configuration at the core of Vielight’s technology.
What the Researchers Concluded
The authors describe home-based itPBM as safe, well tolerated, and feasible, with preliminary efficacy signals across cognitive, metabolic, and network-level measures. Adherence was high — 96.9% in the active group, with no serious adverse events and only mild, self-resolving effects — which matters for a device meant to be used at home, unsupervised, six days a week. They position it as a mitochondria-targeted, non-invasive approach that may eventually complement amyloid-focused therapies by addressing a different mechanism — and they call for larger, double-blind, multicenter trials with longer follow-up to confirm the findings.
Read the full paper: Journal of Alzheimer’s Disease –>
This clinical trial was conducted by:
- Dr Neda Rashidi-Ranjbar, MD, PhD – University of Toronto
- Dr Corinne Fischer, MD, PhD – University of Toronto
Reference: Rashidi-Ranjbar N, et al. A multimodal evaluation of transcranial photobiomodulation in mild cognitive impairment. J Alzheimers Dis. 2026. DOI: 10.1177/13872877261453911.
